Faraz Ali
Chief Executive Officer presso TENAYA THERAPEUTICS, INC.
Patrimonio netto: 1 M $ in data 29/02/2024
Profilo
Faraz Ali is Chief Executive Officer, Secretary & Director at Tenaya Therapeutics, Inc. Mr. Ali is also on the board of Alliance for Regenerative Medicine.
He previously was Chief Business Officer at REGENXBIO, Inc., Vice President-Global Commercial Development at bluebird bio, Inc. and Head-U.S.
Marketing & Strategic Planning at Genzyme Corp.
Mr. Ali received an MBA from Harvard Business School and an undergraduate degree from Stanford University.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
23/02/2024 | 198 079 ( 0.26% ) | 1 M $ | 29/02/2024 |
Posizioni attive di Faraz Ali
Società | Posizione | Inizio |
---|---|---|
TENAYA THERAPEUTICS, INC. | Chief Executive Officer | 01/06/2018 |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Director/Board Member | 01/01/2023 |
Precedenti posizioni note di Faraz Ali
Società | Posizione | Fine |
---|---|---|
REGENXBIO INC. | Corporate Officer/Principal | 05/01/2018 |
BLUEBIRD BIO, INC. | Corporate Officer/Principal | 01/02/2016 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/11/2010 |
Formazione di Faraz Ali
Stanford University | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
REGENXBIO INC. | Health Technology |
BLUEBIRD BIO, INC. | Health Technology |
TENAYA THERAPEUTICS, INC. | Health Technology |
Aziende private | 2 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |